Similar articles for PMID: 18552139

Year	Number of Results
1992	1
1995	2
1996	1
1997	4
1998	6
1999	4
2000	6
2001	3
2002	2
2003	9
2004	5
2005	9
2006	3
2007	3
2008	5
2009	3
2010	1
2011	5
2012	5
2013	7
2014	5
2015	6
2016	7
2017	4
2018	7
2019	6
2020	5
2021	3
2024	0

1

Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.

Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR. Pandit-Taskar N, et al. J Nucl Med. 2008 Jul;49(7):1066-74. doi: 10.2967/jnumed.107.049502. Epub 2008 Jun 13. J Nucl Med. 2008. PMID: 18552139 Free PMC article. Clinical Trial.

2

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Bander NH, et al. J Urol. 2003 Nov;170(5):1717-21. doi: 10.1097/01.ju.0000091655.77601.0c. J Urol. 2003. PMID: 14532761 Clinical Trial.

3

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ. Pandit-Taskar N, et al. EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015. EJNMMI Res. 2015. PMID: 25984435 Free PMC article.

4

Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.

Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH. Smith-Jones PM, et al. J Nucl Med. 2003 Apr;44(4):610-7. J Nucl Med. 2003. PMID: 12679407 Free article.

5

Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.

Wong JY, Chu DZ, Yamauchi D, Odom-Maryon TL, Williams LE, Liu A, Esteban JM, Wu AM, Primus FJ, Beatty JD, Shively JE, Raubitschek AA. Wong JY, et al. J Nucl Med. 1998 Dec;39(12):2097-104. J Nucl Med. 1998. PMID: 9867150 Free article. Clinical Trial.

6

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM. Sharkey RM, et al. J Nucl Med. 2003 Dec;44(12):2000-18. J Nucl Med. 2003. PMID: 14660727 Free article. Clinical Trial.

7

Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.

Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Vallabhajosula S, et al. Prostate. 2004 Feb 1;58(2):145-55. doi: 10.1002/pros.10281. Prostate. 2004. PMID: 14716739

8

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Vallabhajosula S, et al. J Nucl Med. 2005 Apr;46(4):634-41. J Nucl Med. 2005. PMID: 15809486 Free article. Clinical Trial.

9

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Milowsky MI, et al. J Clin Oncol. 2004 Jul 1;22(13):2522-31. doi: 10.1200/JCO.2004.09.154. Epub 2004 Jun 1. J Clin Oncol. 2004. PMID: 15173215 Clinical Trial.

10

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

113 results

Results by year